EUVIMEDEUVIMED entdecken
Open Access

Coexistence of Metabolic Dysfunction‐Associated Fatty Liver Disease and Chronic Kidney Disease Is a More Potent Risk Factor for Ischemic Heart Disease

Daisuke Miyamori, Marenao Tanaka iD, Tatsuya Sato iD, Keisuke Endo, Kazuma Mori, Takuma Mikami iD, Itaru Hosaka, Nagisa Hanawa, Hirofumi Ohnishi, Masato Furuhashi iD

Journal of the American Heart Association · 2023

DOI: 10.1161/jaha.123.030269 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Heart Association, 2023. Verfasst von Daisuke Miyamori und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular, Renal and Metabolic Medicine Sapporo Medical University School of Medicine Sapporo Japan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Non-alcoholic Fatty Liver Disease, Myocardial Ischemia, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Metabolic dysfunction–associated fatty liver disease (MAFLD), defined as fatty liver with overweight/obesity, type 2 diabetes, or metabolic abnormalities, is a newly proposed disease. However, it remains unclear whether the coexistence of MAFLD and chronic kidney disease (CKD) is a more potent risk factor for ischemic heart disease (IHD). Methods and Results We investigated the risk of the combination of MAFLD and CKD for development of IHD during a 10‐year follow‐up period in 28 990 Japanese subjects who received annual health examinations. After exclusion of subjects without data for abdominal ultrasonography or with the presence of IHD at baseline, a total of 14 141 subjects (men/women: 9195/4946; mean age, 48 years) were recruited. During the 10‐year period (mean, 6.9 years), 479 subjects (men/women, 397/82) had new onset of IHD. Kaplan–Meier survival curves showed significant differences in rates of the cumulative incidence of IHD in subjects with and those without MAFLD (n=4581) and CKD (n=990; stages 1/2/3/4–5, 198/398/375/19). Multivariable Cox proportional hazard model analyses showed that coexistence of MAFLD and CKD, but not MAFLD or CKD alone, was an independent predictor for development of IHD after adjustment for age, sex, current smoking habit, family history of IHD, overweight/obesity, diabetes, hypertension, and dyslipidemia (hazard ratio, 1.51 [95% CI, 1.02–2.22]). The addition of the combination of MAFLD and CKD to traditional risk factors for IHD significantly improved the discriminatory capability.

Conclusions

The coexistence of MAFLD and CKD predicts new onset of IHD better than does MAFLD or CKD alone.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Non-alcoholic Fatty Liver DiseaseMyocardial IschemiaRenal Insufficiency, ChronicMaleFemaleHumansMiddle AgedOverweightRisk FactorsObesity

Stichwörter der Autor:innen

chronic kidney diseaseischemic heart diseasemetabolic dysfunction–associated fatty liver disease

Autor:innen und Institutionen

  • Department of Cardiovascular, Renal and Metabolic Medicine Sapporo Medical University School of Medicine Sapporo Japan.
  • Department of Nephrology Asahikawa Red Cross Hospital Asahikawa Japan.
  • Department of Internal Medicine Tanaka Medical Clinic Yoichi Japan.
  • Department of Cellular Physiology and Signal Transduction Sapporo Medical University School of Medicine Sapporo Japan.
  • Department of Immunology and Microbiology National Defense Medical College Tokorozawa Japan.
  • Department of Cardiovascular Surgery Sapporo Medical University School of Medicine Sapporo Japan.

ORCID-Profile: Marenao Tanaka, Tatsuya Sato, Takuma Mikami, Masato Furuhashi

Zitieren

APA

Miyamori, D., Tanaka, M., Sato, T., Endo, K., Mori, K., Mikami, T., Hosaka, I., Hanawa, N., Ohnishi, H., & Furuhashi, M. (2023). Coexistence of Metabolic Dysfunction‐Associated Fatty Liver Disease and Chronic Kidney Disease Is a More Potent Risk Factor for Ischemic Heart Disease. Journal of the American Heart Association. https://doi.org/10.1161/jaha.123.030269

Vancouver

Miyamori D, Tanaka M, Sato T, Endo K, Mori K, Mikami T, et al. Coexistence of Metabolic Dysfunction‐Associated Fatty Liver Disease and Chronic Kidney Disease Is a More Potent Risk Factor for Ischemic Heart Disease. Journal of the American Heart Association. 2023. doi:10.1161/jaha.123.030269

BibTeX
@article{Miyamori2023,
  author = {Miyamori, Daisuke and Tanaka, Marenao and Sato, Tatsuya and Endo, Keisuke and Mori, Kazuma and Mikami, Takuma and Hosaka, Itaru and Hanawa, Nagisa and Ohnishi, Hirofumi and Furuhashi, Masato},
  title = {Coexistence of Metabolic Dysfunction‐Associated Fatty Liver Disease and Chronic Kidney Disease Is a More Potent Risk Factor for Ischemic Heart Disease},
  journal = {Journal of the American Heart Association},
  year = {2023},
  doi = {10.1161/jaha.123.030269}
}
Kostenlos starten →